HILDEN, Germany, & GERMANTOWN, Md.--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the publication of a multicenter clinical study demonstrating the accuracy of ...
Germantown, Maryland, and Venlo, the Netherlands, June 03, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAstat-Dx Gastrointestinal ...
Panel delivers rapid detection of five common bacterial pathogens for outpatient use, aiding fast and informed treatment decisions QIAGEN building momentum in the U.S. syndromic testing market with ...
GERMANTOWN, Md., & VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the U.S. regulatory clearance of the first in a series of QIAstat-Dx ...
QIAGEN N.V. QGEN has secured FDA clearance for its QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, bolstering its syndromic testing portfolio in the United States. This marks the ...
Qiagen has received clearance from U.S. regulators to market its gastrointestinal-illness test. The Netherlands life-sciences and diagnostics company said Thursday that the Food and Drug ...
New QIAstat-Dx Gastrointestinal Panel 2 Mini B&V (bacterial and viral) tailored to provide fast answers for outpatient diagnosis of gastrointestinal conditions QIAGEN the first to offer both ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback